Articles related to RADIOTHERAPY

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.

In a phase 3 trial, osimertinib significantly improved median progression-free survival to 39.1 months in patients with unresectable stage III EGFR-mutated NSCLC following chemoradiotherapy, compared to 5.6 months with placebo.

A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.

In the evolving landscape of radiation oncology, the discussion around supervision models—direct or virtual—presents a pivotal moment for the field. This debate not only impacts patient access and safety but also stresses upon the profession’s adaptability in integrating technology while preserving core clinical standards.

This study reinforces the noninferiority of sentinel node biopsy in patients with clinically node-negative breast cancer, offering a potential paradigm shift in surgical decision-making and patient care.

Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.